3D-PHAD

LIPIDS

CAT No.# CS-CC-00234
Category Lipids
CAS 1699735-79-9
Stock Status
AVAILABLE ENQUIRE NOW View COA

(Available within 3-5 days)

Product maybe under re-certification or re-stock. Enquire now to know exact date of delivery and pricing.
Molecular Weight 1537.11
Molecular Formula C82H158N3O20P
Synonyms: ammonium (2S,3R,4S,5S)-2-(hydroxymethyl)-5-((R)-3-(tetradecanoyloxy)tetradecanamido)-4-(((R)-3-(tetradecanoyloxy)tetradecanoyl)oxy)-6-(((2R,3S,4S,5S,6S)-3,4,6-trihydroxy-5-((R)-3-hydroxytetradecanamido)tetrahydro-2H-pyran-2-yl)methoxy)tetrahydro-2H-pyran-??????????????????????
Application Notes: Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune response.
Shipping: Free Shipping for worldwide on order above 2000 USD
3D-PHAD Worldwide Suppliers of 3D-PHAD Lipids Clearsynth CS-CC-00234

Product rating: 9 3D-PHAD based on 20 ratings

  1. Lipids
  2. 3D-PHAD


PEOPLE ALSO SEARCHED FOR: 1. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
2. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
3. Lauroside D
4. Triazolam 13C D3
5. Icatibant impurity 1
6. BISPHENOL AF (RING-13C12)
7. 0.1% TFA in Water ULC-MS
8. Metamizole EP Impurity C HCl
9. Silodosin Metabolite D4
10. Silodosin Metabolite
11. 2-Phenoxymethanesulfonanilide
12. Nimesulide EP Impurity A
13. Acetone HPLC
14. Riluzole (1604337)
15. Pheniramine impurity B
16. Palbociclib N-Glucuronide
17. Carpropamid
18. Olmesartan N1-Trityl Impurity
19. Aripiprazole (1042634)
20. 2-(p-Tolyl)pyrimidine


This page contains information about 3D-PHAD Cas 1699735-79-9 and its Lipids.

3D-PHAD 3D-PHAD Worldwide Suppliers of 3D-PHAD Lipids Clearsynth 1699735-79-9

"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."